AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Insmed, Inc.
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001S9SKW7
100.60▲ 0.12 (0.12%)
As of 2026-10-09
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
100.48
Day's Range
99.15 – 101.82
52-Week Range
90.39 – 212.75
Volume
2.5M
Avg Volume
2.5M
Share Statistics
Shares Outstanding
Employees
1,664
Exchange
XNAS
Listed
2000-06-01
Share count as of July 31, 2026

Insmed, Inc. (INSM) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Insmed, Inc. (INSM)
What is Insmed, Inc.'s Market Cap?
Insmed, Inc.'s Market Cap is $22.0B, based on as-reported figures from SEC (XBRL) filings.
What is Insmed, Inc.'s Enterprise Value?
Insmed, Inc.'s Enterprise Value is $21.4B, based on as-reported figures from SEC (XBRL) filings.
What is Insmed, Inc.'s Price / Sales?
Insmed, Inc.'s Price / Sales is 19.3×, based on as-reported figures from SEC (XBRL) filings.
What is Insmed, Inc.'s EV / Revenue?
Insmed, Inc.'s EV / Revenue is 18.8×, based on as-reported figures from SEC (XBRL) filings.
What is Insmed, Inc.'s EV / EBITDA?
Insmed, Inc.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Insmed, Inc.'s Revenue (TTM)?
Insmed, Inc.'s Revenue (TTM) is $1.1B, based on as-reported figures from SEC (XBRL) filings.
What is Insmed, Inc.'s Net Income (TTM)?
Insmed, Inc.'s Net Income (TTM) is -$875.3M, based on as-reported figures from SEC (XBRL) filings.
What is Insmed, Inc.'s EBITDA?
Insmed, Inc.'s EBITDA is -$820.8M, based on as-reported figures from SEC (XBRL) filings.
What is Insmed, Inc.'s Diluted EPS (TTM)?
Insmed, Inc.'s Diluted EPS (TTM) is -4.01, based on as-reported figures from SEC (XBRL) filings.
What is Insmed, Inc.'s EBITDA Margin?
Insmed, Inc.'s EBITDA Margin is -72.1%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · INSMAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Product revenues, net
YoY growth+296.1%+229.6%+152.6%+52.4%
Operating expenses:
Cost of product revenues (excluding amortization of intangible assets)
Research and development
Selling, general and administrative
Amortization of intangible assets
Change in fair value of contingent consideration
Total operating expenses
% of revenue100.4%150.1%221.2%357.1%
Operating loss
% of revenue-0.4%-50.1%-121.2%-257.1%
Investment income
Interest expense
Other (expense) income, net
Loss before income taxes
Provision for income taxes
Net loss
% of revenue-3.1%-53.5%-124.5%-260.0%
Basic net loss per share (in dollars per share)
Diluted net loss per share (in dollars per share)